The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II study of sorafenib in Japanese patients with hepatocellular carcinoma and Child Pugh A or B cirrhosis.
Eiichiro Suzuki
No relevant relationships to disclose
Shuichi Kaneko
No relevant relationships to disclose
Takuji Okusaka
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Research Funding - Bayer
Masafumi Ikeda
Honoraria - Taiho Pharmaceutical
Kensei Yamaguchi
No relevant relationships to disclose
Michihisa Moriguchi
No relevant relationships to disclose
Tosiya Sato
No relevant relationships to disclose
Junji Furuse
Consultant or Advisory Role - Bayer (U)
Research Funding - Bayer